Yeast Infections and UTIs on a GLP-1: What the Evidence Actually Shows

The short version

A lot of women are asking whether their GLP-1 is behind a yeast infection or a UTI. It is one of the most-typed questions about these drugs that almost nobody has written a careful answer to.

The careful answer is this: the strong, well-documented genitourinary infection signal belongs to a different class of diabetes medicine — SGLT2 inhibitors — and not to GLP-1s. That distinction matters enormously, because a great many people with type 2 diabetes take one of each, and the drug getting blamed is often not the drug responsible.

What follows is what the labels say, what the literature supports, and — honestly — what is left unexplained.

What the GLP-1 labels actually say

I read the current prescribing information rather than working from memory, because this is precisely the kind of claim that gets repeated into existence.

• Wegovy (semaglutide): the label contains no mention of candidiasis, vaginal infection, vulvovaginal infection, or genital mycotic infection. Urinary tract infection appears once — in the adverse-reactions table, at 4% on Wegovy against 2% on placebo¹.
• Zepbound (tirzepatide): the label contains none of those terms at all, urinary tract infection included².

So: no genital fungal infection warning on either. A small numerical difference in UTI on one of them, in a trial population, with no dedicated warning attached.

What the SGLT2 label says, for contrast

Now the same exercise on empagliflozin, an SGLT2 inhibitor:

The label carries an entire warnings subsection — 5.6, Genital Mycotic Infections — stating plainly that the drug increases the risk, and enumerating vulvovaginal mycotic infection, vaginal infection, vulvitis, vulvovaginal candidiasis and genital candidiasis among the reactions. It also carries warnings for urosepsis and pyelonephritis, and directs clinicians to evaluate patients for signs of urinary tract infection³.

That is not a subtle difference in emphasis. One class has a named warning section for exactly this; the other does not mention it.

The mechanism explains why. SGLT2 inhibitors work by making you excrete glucose in your urine. Sugar in the urogenital tract is food for yeast, which is the entire reason the association exists. GLP-1s do not do that. The population-based work on SGLT2 inhibitors and severe urinary tract infection sits in this same literature⁴.

So why do so many women on a GLP-1 get thrush?

Because "the drug did not cause it" is not the same as "nothing is happening." Several things can be true at once:

You may be on both. Combination therapy with an SGLT2 inhibitor and a GLP-1 is common in type 2 diabetes. If you are, the genital-infection risk in your medicine cabinet is real — it is just attached to the other prescription.

Diabetes itself is associated with this. Independent of any drug, women with type 2 diabetes have higher rates of vaginal candida colonisation and vulvovaginal symptoms; a study evaluating symptoms and colonisation in women with type 2 diabetes documents that relationship⁵. Glycaemic control is part of the picture before you add any medicine to it.

Rapid weight loss changes the tissue and the environment. This is the honest, under-evidenced part, and I am not going to dress it up: there is no good GLP-1-specific human research on the vulvovaginal microenvironment during rapid weight reduction. What women report — dryness, irritation, a changed sense of things "down there" — is real and consistent, and the mechanism most often invoked (oestrogen, fat mass, tissue change) is extrapolated from other contexts, not demonstrated in people taking these drugs. Nobody has studied it properly. Anyone telling you otherwise is guessing with more confidence than the evidence allows.

What this means practically

• A yeast infection or UTI on a GLP-1 is worth treating on its own merits, and worth mentioning to your clinician — but it is not a documented effect of the drug in the way it is for SGLT2 inhibitors.
• If you take both classes, say so when you are asked what you are on. It changes the differential.
• Recurrent infections deserve a proper workup rather than being attributed to whichever medicine you started most recently. Recurrence is a reason to look at glycaemic control, not just at the newest prescription.
• If symptoms are dryness and irritation rather than infection, that is a different conversation, and it is one where the published evidence genuinely runs out.

For the broader picture of what these drugs do and do not do, I keep the day-to-day side-effect guide, the cycle and reproductive-hormone evidence, and the PCOS evidence review.